Piper Jaffray Keeps a Sell Rating on Valeant Pharma

By Carrie Williams

In a report issued on September 15, David Amsellem from Piper Jaffray reiterated a Sell rating on Valeant Pharma (NYSE: VRX), with a price target of $14. The company’s shares closed on Friday at $13.92.

According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -0.9% and a 46.7% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Amphastar Pharmaceuticals.

Valeant Pharma has an analyst consensus of Hold, with a price target consensus of $17.36.

The company has a one year high of $27.84 and a one year low of $8.31. Currently, Valeant Pharma has an average volume of 16.82M.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. It operates through the following segments: The Bausch + Lomb/International, The Branded Rx, and The U.S.